DK3615023T3 - Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade - Google Patents

Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade Download PDF

Info

Publication number
DK3615023T3
DK3615023T3 DK18724073.4T DK18724073T DK3615023T3 DK 3615023 T3 DK3615023 T3 DK 3615023T3 DK 18724073 T DK18724073 T DK 18724073T DK 3615023 T3 DK3615023 T3 DK 3615023T3
Authority
DK
Denmark
Prior art keywords
neurodegenerated
lipoyl
glu
ala
treatment
Prior art date
Application number
DK18724073.4T
Other languages
English (en)
Inventor
Alexander Baguisi
Reinier Beeuwkes
Ralph Casale
David A Dewahl Jr
Steven A Kates
Alan S Lader
Original Assignee
Ischemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix Llc filed Critical Ischemix Llc
Application granted granted Critical
Publication of DK3615023T3 publication Critical patent/DK3615023T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18724073.4T 2017-04-25 2018-04-25 Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade DK3615023T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489735P 2017-04-25 2017-04-25
PCT/US2018/029372 WO2018200680A1 (en) 2017-04-25 2018-04-25 Compositions and methods for treating traumatic brain injury

Publications (1)

Publication Number Publication Date
DK3615023T3 true DK3615023T3 (da) 2023-09-25

Family

ID=62148517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18724073.4T DK3615023T3 (da) 2017-04-25 2018-04-25 Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade

Country Status (9)

Country Link
US (3) US10744115B2 (da)
EP (2) EP3615023B1 (da)
JP (2) JP7203756B2 (da)
CN (1) CN110913851B (da)
AU (2) AU2018258158A1 (da)
CA (1) CA3061203A1 (da)
DK (1) DK3615023T3 (da)
ES (1) ES2952834T3 (da)
WO (1) WO2018200680A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240124520A1 (en) * 2019-10-16 2024-04-18 The Board Of Trustees Of The Leland Stanford Junior University N-acylated histidine dipeptides as anticancer agents

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (de) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5288706A (en) 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
PT95826B (pt) 1989-11-09 1997-11-28 Asta Medica Ag Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
ATE202490T1 (de) 1992-04-24 2001-07-15 Biocompatibles Ltd Verfahren zur verminderung von mikroorganismenhaftung
DE4235912C2 (de) 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
WO1997000889A1 (fr) 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides de liaison de lipoproteines de faible densite
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
WO1998010090A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
AU728488B2 (en) 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (de) 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
JP2000169371A (ja) 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
AU6462500A (en) 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU781678C (en) 1999-11-18 2005-12-22 Ischemix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
WO2001080851A1 (en) 2000-04-21 2001-11-01 United States Army Medical Research And Materiel Command Method of treating, preventing or inhibiting central nervous system injuries and diseases
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
DE60234164D1 (de) 2001-03-19 2009-12-10 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
CA2448062A1 (en) 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (ja) 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
WO2003055853A1 (fr) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Composes accepteurs d'electrons pouvant former des monocouches autoassemblees
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003219880A1 (en) 2002-02-22 2003-09-09 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
ATE408398T1 (de) 2002-07-29 2008-10-15 Nanodel Technologies Gmbh Nanopartikele für dna verabreichung zu einem zielorgan
US8603345B2 (en) 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
KR100811969B1 (ko) 2004-02-18 2008-03-10 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 당쇄 리간드 복합체, 및 그 리간드 복합체를 이용한단백질의 분석 방법
JP2006022066A (ja) 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
EP1957093B1 (en) * 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
JP2009507848A (ja) 2005-09-09 2009-02-26 オレゴン ヘルス アンド サイエンス ユニバーシティ 神経保護薬
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US20080051691A1 (en) 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
WO2010052310A1 (en) 2008-11-07 2010-05-14 Segix Italia S.R.L. Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
DK2821405T3 (da) 2009-06-15 2016-07-25 Encore Health Llc Cholinestere til behandling af presbyopi og katarakt
EP4082542A1 (en) 2009-06-15 2022-11-02 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
KR20140020840A (ko) 2010-11-18 2014-02-19 이쉐믹스 엘엘씨 허혈성 손상을 치료하기 위한 리포일 화합물 및 이의 용도
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds

Also Published As

Publication number Publication date
CA3061203A1 (en) 2018-11-01
CN110913851B (zh) 2023-08-25
AU2024202147A1 (en) 2024-05-02
US20200352904A1 (en) 2020-11-12
US10744115B2 (en) 2020-08-18
EP4282411A1 (en) 2023-11-29
US11213509B2 (en) 2022-01-04
EP3615023A1 (en) 2020-03-04
CN110913851A (zh) 2020-03-24
JP2023030158A (ja) 2023-03-07
US20220280477A1 (en) 2022-09-08
AU2018258158A1 (en) 2019-11-21
WO2018200680A1 (en) 2018-11-01
JP2020517731A (ja) 2020-06-18
US20180303796A1 (en) 2018-10-25
ES2952834T3 (es) 2023-11-06
JP7203756B2 (ja) 2023-01-13
EP3615023B1 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3524255T3 (da) Sammensætning til behandling af acne
BR112016022976A2 (pt) Métodos para o tratamento de hcv
ES2973214T3 (es) Retractor quirúrgico
DK3307267T3 (da) Behandling af multipel sklerose
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3416580T3 (da) Enhed til bestråling af huden
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme